戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (left1)

通し番号をクリックするとPubMedの該当ページを表示します
1 utcome was the proportion of patients with a CIDP relapse or who were withdrawn for any other reason
2  patients with IgM monoclonal antibodies and CIDP reacted to an epitope spanning aa 301-314 of beta-t
3 f the immune attack in patients with GBS and CIDP.
4 icipate in the pathologic process of GBS and CIDP.
5               In Guillain-Barre syndrome and CIDP intravenous immunoglobulin is equivalent to but mor
6 his study, the largest reported trial of any CIDP treatment, shows the short-term and long-term effic
7 ncern for the clinician when misdiagnosed as CIDP, in view of the therapeutic implications.
8 mmatory demyelinating polyneuropathy (CIDP), CIDP associated with human immunodeficiency virus infect
9 eflect the different pathophysiology of each CIDP subtype.
10           Recent trials for other agents for CIDP treatment have not proved as promising, with a larg
11  and individualised treatment strategies for CIDP.
12  and supports use of IGIV-C as a therapy for CIDP.
13 g can be used as a maintenance treatment for CIDP.
14 the use of IVIG (Gamunex) as a treatment for CIDP.
15 ssays, we showed that the IgGs from the four CIDP patients prevented adhesive interaction between con
16 tributes that might differentiate POEMS from CIDP and lead to earlier therapeutic intervention were e
17 cificity of 77% in discriminating POEMS from CIDP.
18 e was a striking synchronization between her CIDP and vestibulopathy with respect to clinical course
19                     However, in CIDP and HIV-CIDP, but not the other diseases, there was prominent up
20  human immunodeficiency virus infection (HIV-CIDP), IgM paraproteinaemic neuropathy and normal or non
21    Corticosteroid treatment is beneficial in CIDP, but not in Guillain-Barre syndrome and may worsen
22                                  However, in CIDP and HIV-CIDP, but not the other diseases, there was
23  that these ligands were upregulated only in CIDP.
24  with the Medical Research Council scale, in CIDP (rho=0.88, p<0.001) and also in CMT1A (rho=0.50, p<
25 A-DR antigen, the findings indicate that, in CIDP, Schwann cells possess the necessary markers to fun
26 and the heterogeneous response to therapy in CIDP.
27            138 POEMS patients and 69 matched CIDP controls were compared.
28 from 1960 to 2007 were compared with matched CIDP controls.
29                    Demyelinating neuropathy (CIDP or MMN) occurred in close to 30% of the patients, i
30 patients's relapsing and remitting course of CIDP and vestibulopathy was assessed by quantitative mus
31 umoral immune systems in the pathogenesis of CIDP will be discussed.
32 tion) along the nerve where the pathology of CIDP is probably predominantly proximal and distal.
33                We examined the reactivity of CIDP patients' sera against neuronal antigens and used i
34 paranodes may participate in the severity of CIDP.
35         According to the clinical subtype of CIDP, typical CIDP patients showed symmetric and root-do
36                  While the abiding theory of CIDP pathogenesis is that cell-mediated and humoral mech
37 s immunoglobulin (IVIG) for the treatment of CIDP and the US Food and Drug Administration approved th
38 ch is to our knowledge, the largest trial of CIDP to date and the first to study two administrations
39 iously been investigated in a large trial of CIDP.
40                                     No other CIDP patient or any of the 104 controls with other neuro
41 c inflammatory demyelinating polyneuropathy (CIDP) are conditions that affect peripheral nerves.
42 c inflammatory demyelinating polyneuropathy (CIDP) has occasionally been associated with clinical or
43 c inflammatory demyelinating polyneuropathy (CIDP) need long-term intravenous immunoglobulin.
44 c inflammatory demyelinating polyneuropathy (CIDP) were compared with 10 healthy subjects.
45 c inflammatory demyelinating polyneuropathy (CIDP), CIDP associated with human immunodeficiency virus
46 c inflammatory demyelinating polyneuropathy (CIDP), magnetic resonance neurography with 3-dimensional
47 c inflammatory demyelinating polyneuropathy (CIDP).
48 c inflammatory demyelinating polyneuropathy (CIDP).
49 c inflammatory demyelinating polyneuropathy (CIDP).
50 c inflammatory demyelinating polyneuropathy (CIDP).
51 matory demyelinating polyradiculoneuropathy (CIDP) and multifocal motor neuropathy with conduction bl
52 matory demyelinating polyradiculoneuropathy (CIDP) but long-term effects have not been shown.
53 matory demyelinating polyradiculoneuropathy (CIDP) is a frequent autoimmune neuropathy with a heterog
54 matory demyelinating polyradiculoneuropathy (CIDP) is an inflammatory neuropathy, classically charact
55 matory demyelinating polyradiculoneuropathy (CIDP) shows autoantibodies to contactin (1).
56 matory demyelinating polyradiculoneuropathy (CIDP), will be discussed.
57 matory demyelinating polyradiculoneuropathy (CIDP).
58             Adults with definite or probable CIDP who responded to intravenous immunoglobulin treatme
59 re many phenotypic variants, suggesting that CIDP may not be a discrete disease entity but rather a s
60 relationship of cranial nerve involvement to CIDP remains unclear.
61 ing to the clinical subtype of CIDP, typical CIDP patients showed symmetric and root-dominant hypertr
62  41.5(10.6) p.u. (CMT1A) and 39.3(8.7) p.u. (CIDP).
63                                Compared with CIDP controls, POEMS patients demonstrated: (1) greater
64                                Compared with CIDP, there is greater axonal loss (reduction of motor a
65           Four of 46 sera from patients with CIDP reacted strongly against hippocampal neurons (8.6%)
66                            117 patients with CIDP who met specific neurophysiological inflammatory ne
67 1 complex occur in a subset of patients with CIDP who share common clinical features.
68 lemtuzumab) showing benefit in patients with CIDP, but the side effect profiles can be worrisome.
69 -term and long-term benefit in patients with CIDP.
70 are found in about one-half of patients with CIDP.

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。